1156. BioFire FilmArray Decreases Infection Control Isolation Times by 4 days in ICU, BMT and Respiratory Wards
Session: Poster Abstract Session: Diagnostics: Viral
Friday, October 6, 2017
Room: Poster Hall CD


Novel, rapid, syndromic testing of patients presenting with respiratory infections has the potential to improve patient access and care by decreasing time to diagnosis.  BioFire FilmArray (BioFire Diagnostics, bioMerieux) is a cartridge-based, multiplex PCR platform capable of detecting 17 viral and 3 bacterial targets in one hour.  This study assessed the impact of implementing this technology on the duration of infection control isolation. 


A randomized control trial in a 900-bed tertiary-care academic hospital was conducted between December 2016 and January 2017.  Fifty consecutive samples of patients with respiratory infections on our ICU, BMT and Respiratory wards to received either BioFire FilmArray Respiratory Panel (BF) diagnostic testing or our routine diagnostic testing (RO) consisting of an influenza A/B/RSV PCR (in-house) followed by Luminex NxTag Respiratory Pathogen Panel that was batched at a reference lab.  Five patient charts with missing data were excluded from analysis.  Statistical analysis was completed using RStudio Version 1.0.136 – © 2009-2016 RStudio, Inc.


Patients randomized to the BF arm remained on respiratory isolation precautions on average (42.3h +/- 72.9h) over 100 hours less than patients randomized to the routine arm (151.3h +/- 151.8h) (95%CI:  35.6-184.4h, P=0.0052).


Implementing the BioFire FilmArray Respiratory Panel decreased infection control isolation time by approximately 4 days compared to routine testing; further study is warranted to determine the impact of this technology on patient outcomes and cost benefit.

Table 1: Mean Hours in Respiratory Isolation is Statistically Significantly Decreased with BioFire FilmArray Respiratory Panel



Mean (h)

SD (h)

Median (h)

95% CI*

P value*






35.6 - 184.4







*Welch two-sample t-test (assumed unequal variance), significance set at p≤0.05

Figure 1: The majority of patients randomized to receive BioFire testing were in respiratory isolation for less than 50 hours.


Titus Wong, MD, MHSc, FRCPC1,2, Aleksandra Stefanovic, MD, FRCPC1,2, Kerstin Locher, PhD1,2, Elizabeth Bryce, MD, FRCPC1,2, Jennifer M. Grant, MDCM, FRCPC1,2, Eithne Connolly, RN1, Tracey Woznow, BSc1, Marthe Charles, MD, FRCPC1,2, Linda Mn Hoang, MD, FRCPC2,3, Agatha Jassem, PhD, ABMM2,3 and Diane Roscoe, MD FRCPC1,2, (1)Pathology and Laboratory Medicine, Vancouver Coastal Health, Vancouver, BC, Canada, (2)University of British Columbia, Vancouver, BC, Canada, (3)BCCDC Public Health Microbiology and Reference Laboratory, Provincial Health Services Authority, Vancouver, BC, Canada


T. Wong, bioMerieux: Investigator , Research grant

A. Stefanovic, bioMerieux: Investigator , Research grant

K. Locher, None

E. Bryce, bioMerieux: Investigator , Research grant

J. M. Grant, bioMerieux: Investigator , Research grant

E. Connolly, None

T. Woznow, None

M. Charles, None

L. M. Hoang, None

A. Jassem, None

D. Roscoe, bioMerieux: Investigator , Research grant

See more of: Diagnostics: Viral
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.